Follicum AB (“Follicum” or “the Company”) today announced that all patients in the Phase IIa clinical trial with FOL-005 for stimulating hair growth have been recruited. The trial is conducted at the Clinical Research Center for Hair and Skin Science (“CRC”) in Berlin and Bioskin, Hamburg, Germany. The objective is to investigate the safety and effect of different doses of the drug candidate FOL-005 on scalp.
FOL-005 is a modified, short version of the endogenous protein, osteopontin. In the recently completed phase I/IIa study, FOL-005 was shown to be a safe and effective treatment, with 3 out of 4 subjects responding with increased hair growth. In the ongoing study, the patients are treated with different doses of the drug candidate FOL-005 or placebo, administered as injections at two sites on the scalp. Injections are given three times per week for three months. The study is expected to be completed in late 2018.
Jan Alenfall, CEO comments:
“We are very pleased to note that all patients are recruited and that we are slightly ahead of plan. Our intention with the current clinical trial is to confirm recently documented results, where we saw both good effect and safety with FOL-005, as well as a very high patient response. We are looking forward to being able to present the results by the end of this year”.
For further information, please contact:
Jan Alenfall – CEO, Follicum AB
Telephone: +46 46 19 21 97
This information is information that Follicum is obliged to make public according to the EU Market Abuse Regulation. The information was provided through the agency of the contact persons above, for publication on the 4th June 2018.
About Clinical Research Center for Hair and Skin Science (CRC), Berlin, Germany
The Clinical Research Center for Hair and Skin Science (“CRC”) is part of the skin clinic at the Charité University Hospital in Berlin. CRC conducts experimental research and offers specialist expertise in the field of skin and hair research. CRC has conducted a number of clinical studies in various hair indications and has a solid qualification area specializing in clinical phase I and II studies.
About bioskin, Hamburg, Germany
bioskin is a full-service CRO specializing in dermatology that provides services for clinical development of dermatologically oriented products, especially for both early phase/PoC and late phase studies. bioskin has 25 years of experience in clinical studies in this area. Bioskin has previously conducted several clinical studies in various hair indications and has impressive qualifications. The head office is located in Hamburg and is privately owned.
About Follicum AB
Follicum is a biotech company focused on the discovery and development of peptide-based drugs. The primary focus is in hair growth stimulation, where Follicum has obtained very promising results with FOL-005 in a recently completed clinical trial. In diabetes, the drug candidate FOL-014 has demonstrated an increase in insulin release in pre-clinical models. The company was founded in 2011, and is based in Lund, Sweden. Follicum is listed on the Swedish small cap exchange Aktietorget since 2014. www.follicum.com